Compound Kushen Injection (CKI) is Sophora Flavescens and Heterosmilacis Japonicae extract. Meta-analysis confirmed that CKI plus transcatheter arterial chemoembolization (TACE) is more superior to TACE alone for unresectable hepatocellular carcinoma (UHCC) patients.
Introduction
Hepatocellular carcinoma is one of the commonest forms of malignancies. Its global morbidity ranks the seventh, while mortality is at fourth position in the world. Statistics from the World Health Organization (WHO, 2008) show that 749,744 cases of hepatocellular carcinoma were diagnosed, of these, 695,726 cases died in 2008. Southern Africa, Southeast Asia and the Mediterranean coast is the high incidence area of hepatocellular carcinoma. Hepatocellular carcinoma has been the second leading cause of death by cancer in China, there were 372,079 deaths in 2008 (Ferlay et al., 2008) . However, due to the spread of hepatitis B, the incidence and mortality of hepatocellular carcinoma also show a rising trend (Liaw et al., 1986 ).
For unresectable hepatocellular carcinoma (UHCC) patients, most of them are at an advanced stage, few meaningful therapeutic options are available (Bruix et al., 2002) . TACE is considered as a primary and complementary measure for the treatment of UHCC (Roche et al., 2003; Stuart, 2003; Venook et al., 1990 ). However, the adverse events of TACE, such as post embolization syndrome, hepatic insufficiency and myelosuppression, are frequent leads to interruption of TACE treatment (Chung et al., 1996) . As a result, searching new drugs which can combine with TACE to enhance the therapeutic effects and reduce its adverse events has become a hotspot.
Many clinical trials showed that CKI plus TACE can reduce the adverse reactions and improve quality of life for UHCC (Chen, 2009; Tong, 2010; Zhang et al., 2006; Zhu and Li, 2006) . CKI was extracted from the mixture of Sophora flavescens and Heterosmilacis Japonicae with the mass ratio of 7 than 3. Experimental studies confirmed that CKI has significant killing effect on the tumor cells, such as Hep, H22, LAC and Lewis in vitro (Lin et al., 2009 Until now, however, rigorously designed, randomized, large, multi-center, double-blind, controlled trials for UHCC have not been reported.
The purpose of this meta-analysis is to evaluate whether CKI enhances therapeutic effects for UHCC after TACE. It is anticipated that this systematic review will provide evidence-based information for clinical practice.
Materials and Methods

Criteria for Inclusion and Exclusion
The articles were read by two reviewers (Qizhe Sun and Yuan Gao) and studies were selected systematically according to the following criteria: (1) hepatocellular carcinoma patients were confirmed cytologically or pathologically, or diagnosed by CT; (2) trials were described as randomized clinical trials (RCTs); (3) published trials included a treatment group receiving CKI plus TACE and a control group receiving TACE; and (4) the published data of primary interest were tumor response and quality of life for calculation of the odds ratio (OR) at a 95% confidence interval (CI). Trials were excluded if they did not meet the criteria above and included the following: (1) involved animal studies or in vitro studies; (2) did not represent primary research (review articles, letters to the editor, etc); or (3) represented duplicate publications of other studies previously identified in our systematic evaluation.
Literature Search Strategy
Retrieval of trials was performed through the Cochrane Database of Systematic Reviews (The Cochrane 
Outcome Measurements
The main outcome measurements were as follows: (1) Tumor response was evaluated according to the WHO standard for evaluating therapeutic efficacy on solid tumors (Therasse, 2002) . Based on the degree of tumor regression, efficacy was evaluated as following: CR (complete response, CT and/or MRI revealed complete clearance of the lesion); PR (partial response, lesion decreased more than 50%); SD (lesion decreased less than 50% or increased less than 25%); PD (size of lesion increased more than 25% after treatment). Tumor responses were defined as CR+PR. (2) Quality of life was evaluated according to the Karnofsky performance score (KPS) (Yates et al., 1980) , which was classified as: Improvement (KPS improved ≥10 points after treatment)；Stabilization (KPS improved ＜10 points or decreased ＜10 points); Deterioration (KPS decreased ≥10 points after treatment). (3) One-year survival. (4) Adverse events were evaluated, based on the WHO criteria for evaluation of acute and subacute toxic and adverse reactions (Miller et al., 1981) .
Review Methods
Data extraction
The trials selection and the data extraction were performed independently by two investigators. For conflicts, an agreement was reached by discussion among reviewers. The following information was collected from each study: (1) the information about patients (the number of patients allocated, clinical stage, and KPS); (2) the characteristics of methods (the randomization procedure, concealment of allocation, blinding procedure, withdrawal and reasons, and protection against contamination); (3) The characteristics of interventions (dosage and duration of therapy, TACE course, and any co-interventions; (4) the outcomes (tumor response, quality of life, one-year survival and adverse events).
Quality assessment
Methodological quality was evaluated according to the Cochrane Handbook for Systematic Reviews of Interventions (Version 5. 
Results
Common characteristics
The initial search identified 795 trials for possible inclusion in the review, but all of these trials were reported In terms of quality, all trials mentioned "randomization," but none stated the generation of a random allocation sequence.
No trials described information on allocation concealment and blinding. No trials reported the withdrawals and dropouts. 
Sensitivity Analysis
Sensitivity analysis was performed by comparing fixed-effects versus random-effects. In the primary analysis, outcome on quality of life was applied to the fixed-effects model (OR=2.47; 95% CI [1.77, 3 .44]; P < 0.00001). Therefore, a random-effects model was used to re-analyzed it (OR= 2.45; 95% CI [1.75, 3 .43]; P < 0.00001). The results were virtually identical.
Publication Bias
We used the funnel plot to access the publication bias of literatures ( Figure 5 ). The shape of the funnel plots seemed symmetric, and suggesting there was no obvious publication bias. The results show that TACE plus CKI seemed superior to TACE alone for UHCC in respect to patients' tumor response, quality of life and one-year survival. Although quality of included literature are low, the results of this study present credible evidence that the administration of CKI plus TACE is worthy of additional study. Hence, larger, longer-term, rigorously designed, multi-center, randomized, double-blind, controlled trials are required to fully assess whether CKI plus TACE is more outstanding than TACE alone.
DISCUSSION
There are some limitations in this meta-analysis. Due to all literatures we found were of poor methodological quality, the definite conclusions could not be made base on our data. All included trials mentioned "randomized," but all of them did not describe the information of randomization sequence generation, allocation concealment, and blinding. All included literatures did not report the withdrawals and dropouts. We found that the number of patients in experimental group and control group has no change before and after treatment. So it is possible that there are no withdrawals and dropouts happened. However, the evaluation of one-year survival should be interpreted with caution.
